We are live on
!
Find out more
HI
Humankind Investments Portfolio holdings
AUM
$175M
1-Year Est. Return
14.3%
This Fund
S&P 500
This Quarter
Est. Return
+3.44%
1 Year Est. Return
+14.3%
3 Year Est. Return
+46.43%
5 Year Est. Return
+54.92%
10 Year Est. Return
–
AUM
$223M
AUM Growth
-$214M
(-49%)
Cap. Flow
-$220M
Cap. Flow
% of AUM
-98.57%
Top 10 Holdings %
Top 10 Hldgs %
86.7%
Holding
153
New
–
Increased
3
Reduced
4
Closed
135
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$8.12M |
| 2 |
Sony
SONY
|
+$1.12M |
| 3 |
iShares ESG Advanced MSCI EAFE ETF
DMXF
|
+$6.79K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HKND
Humankind US Stock ETF
HKND
|
+$98.4M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$7.46M |
| 3 |
Apple
AAPL
|
+$5.83M |
| 4 |
Archer Daniels Midland
ADM
|
+$5.2M |
| 5 |
AbbVie
ABBV
|
+$3.89M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.74% |
| 2 | Consumer Discretionary | 0% |
| 3 | Consumer Staples | 0% |
| 4 | Financials | 0% |
| 5 | Healthcare | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
JPMorgan Chase
JPM
$950B
| – | – |
-3,476
| Closed | -$1.1M |
|
|
K
102
DELISTED
Kellanova
K
| – | – |
-8,319
| Closed | -$682K |
|
103
Kenvue
KVUE
$36.9B
| – | – |
-31,039
| Closed | -$504K |
|
104
Lennar Class B
LEN.B
$20.8B
| – | – |
-1,693
| Closed | -$203K |
|
105
Labcorp
LH
$25.9B
| – | – |
-5,744
| Closed | -$1.65M |
|
106
Eli Lilly
LLY
$1.06T
| – | – |
-4,959
| Closed | -$3.78M |
|
107
Lowe's Companies
LOW
$125B
| – | – |
-1,436
| Closed | -$361K |
|
108
Lam Research
LRCX
$390B
| – | – |
-1,675
| Closed | -$224K |
|
109
Lumen
LUMN
$6.44B
| – | – |
-39,144
| Closed | -$240K |
|
110
Lamb Weston
LW
$7.19B
| – | – |
-4,806
| Closed | -$279K |
|
111
McKesson
MCK
$101B
| – | – |
-1,111
| Closed | -$858K |
|
112
Mondelez International
MDLZ
$79.9B
| – | – |
-9,413
| Closed | -$588K |
|
113
MetLife
MET
$62.1B
| – | – |
-3,868
| Closed | -$319K |
|
114
The Mosaic Company
MOS
$7.33B
| – | – |
-60,946
| Closed | -$2.11M |
|
115
Merck
MRK
$318B
| – | – |
-26,067
| Closed | -$2.19M |
|
116
Moderna
MRNA
$23.6B
| – | – |
-9,704
| Closed | -$251K |
|
117
Morgan Stanley
MS
$340B
| – | – |
-2,941
| Closed | -$468K |
|
118
Micron Technology
MU
$991B
| – | – |
-2,028
| Closed | -$339K |
|
119
Organon & Co
OGN
$3.57B
| – | – |
-16,672
| Closed | -$178K |
|
120
Opko Health
OPK
$1.02B
| – | – |
-114,644
| Closed | -$178K |
|
121
Oracle
ORCL
$423B
| – | – |
-1,014
| Closed | -$285K |
|
122
PepsiCo
PEP
$190B
| – | – |
-6,928
| Closed | -$973K |
|
123
Pfizer
PFE
$153B
| – | – |
-94,931
| Closed | -$2.42M |
|
124
Procter & Gamble
PG
$339B
| – | – |
-17,581
| Closed | -$2.7M |
|
125
Progressive
PGR
$125B
| – | – |
-988
| Closed | -$244K |
|
Similar funds
MWM
BCVI
CC
BW
DWA
APCM
RWA
BC
Humankind Investments's Q4 2025 Portfolio in Review
As of Q4 2025, Humankind Investments held 153 positions worth $223M, down 49% from $437M the previous quarter. Its ten largest holdings account for 87% of the portfolio.
Humankind Investments withdrew a net $220M in Q4 2025, closing 135 positions and reducing 4 holdings. Its most notable exit was Humankind US Stock ETF, an estimated $98.4M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
Against the trend, Humankind Investments added an estimated $8.12M to iShares Biotechnology ETF.
- Humankind Investments added most to iShares Biotechnology ETF in Q4 2025, an estimated $8.12M increase.
- Humankind Investments's biggest Q4 2025 reduction was Apple, cutting an estimated $5.83M.
- Humankind Investments fully exited Humankind US Stock ETF in Q4 2025, selling an estimated $98.4M.
- Humankind Investments's ten largest holdings make up 87% of its $223M portfolio in Q4 2025.
- Humankind Investments opened 0 new positions and closed 135 in Q4 2025.
- Humankind Investments's portfolio value fell 49% quarter-over-quarter to $223M.
Based on Humankind Investments's 13F filing for Q4 2025, filed 17 Feb 2026.